

RECEIVED

2005 APR 25 P 4: 12

OFFICE OF INTERNATIONAL  
CORPORATE FINANCE



CARL ZEISS MEDITEC

Carl Zeiss Meditec AG 07740 Jena

Securities and Exchange Commission  
Division of Corporation Finance  
Office of International Corporate Finance  
450 Fifth Street, N. W.

Washington, D. C. 20549  
United States

Division/ Dept.: Investor Relations  
Your contact: Jens Brajer

File No. 82-34817

Dear Ladies and Gentlemen,

Please find attached the following document that was released to our shareholders:

Type of document	Date of release
Press release	2005-04-15

Best regards,

Carl Zeiss Meditec AG  
i. V.

Jens Brajer  
Director Investor Relations

i. A.

Mandy Treffer  
Assistant Investor Relations

PROCESSED

APR 28 2005

THOMSON  
FINANCIAL

*Handwritten signature/initials*  
4/26

Board of Management:  
Ulrich Krauss (CEO)  
Bernd Hirsch  
Chairman of the Supervisory Board:  
Dr. Michael Kaschke

Deutsche Bank AG Jena  
Account: 62 453 69 (BLZ: 820 700 00)  
SWIFT: DEUT DE 8E  
IBAN: DE90820700000624536900  
Commercial register:  
Gera, HRB 5623  
VAT-IdNo. DE 811 922 737  
Tax-No. 64003/ 02707

Commerzbank Jena  
Account: 258072800 (BLZ: 820 40000)  
SWIFT: COBADEFFXX  
IBAN: DE31820400000258072800  
Phone: +49 (0) 36 41/ 220-0  
Fax: +49 (0) 36 41/ 220-112  
Internet: www.meditec.zeiss.com  
e-mail: info@meditec.zeiss.com



05007492

Carl Zeiss Meditec AG  
Goeschwitzer Strasse 51-52  
07745 Jena  
Germany

Tel: +49 (0) 36 41/220-105

Fax: +49 (0) 36 41/220-117

e-mail: j.brajer@meditec.zeiss.com

Our ref.: JB/Mtr

Date: 2005-04-15

SUPPL



## **Carl Zeiss Meditec – Majority shareholding IOLTECH with good revenues development in past financial year**

**Jena, 15 April 2005** – The French ophthalmic surgery specialist IOLTECH S.A., in which Carl Zeiss Meditec AG (ISIN: DE0005313704) holds a controlling majority of 87 percent, today published its sales revenues for the financial year 2004/2005 (end: February 28, 2005) in accordance with statutory provisions in France. Accordingly, during this period IOLTECH posted a turnover of € 54.1 million (previous year: € 44.7 m). This corresponds to an increase of 21% over the previous year. More than half of the IOLTECH revenues were generated outside its native market, France. Given the fact that integration of IOLTECH and Carl Zeiss Meditec has already commenced, both companies consider this result to be a major success.

As of 1 February 2005, Carl Zeiss Meditec, medical technology supplier listed in the Prime Standard at the Deutsche Börse, had acquired in a first step about 63 percent of the IOLTECH shares from its former majority shareholder Philippe Tourrette. Accordingly, from this date onwards the activities of IOLTECH are reflected in the consolidated financial statements of Carl Zeiss Meditec. In a second step about two thirds of the remaining IOLTECH shareholders agreed to the takeover by Carl Zeiss Meditec by accepting the corresponding takeover bid. Thus, Carl Zeiss Meditec now holds 87.1% of the shares in IOLTECH. Until the takeover of IOLTECH S.A. will have been completed by Carl Zeiss Meditec, the company remains listed on the French stock exchange Euronext.

In accordance with the statutory provisions in France IOLTECH S.A. will submit its full figures for the financial year 2004/2005 in May 2005.



**Brief Profile**

Built on an unparalleled 150-year heritage of optical innovation, Carl Zeiss Meditec AG (International Securities Identification Number DE000531370) is one of the world's leading eye care solutions providers.

Its product line includes systems for the diagnosis and treatment of the four main diseases of the eye: refraction, cataract, glaucoma and retinal disorders. The company has incorporated its technologically-superior optics into a stream of product innovations throughout the years, from slit lamps and fundus cameras to the Humphrey® Field Analyzer, recognised as the global standard for glaucoma detection and management, to its newest applications of lasers as embodied in its leading-edge MEL-80™ refractive laser and innovative STRATUSOCT™ for glaucoma diagnosis.

Carl Zeiss Meditec AG is based in Jena, Germany, with key subsidiaries in the U.S. (Carl Zeiss Meditec, Inc.) and Japan (Carl Zeiss Meditec Ltd.). The rapidly aging global population and other trends are expected to generate long-term growth in the ophthalmic market. The company's activities are focused on applying innovative optical technologies to maintain and enhance vision today and in the future.

31 percent of the Carl Zeiss Meditec shares are in scattered holdings. The remaining 69 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry.

**Contact:**

**Investor relations**

Jens Brajer/Director Investor Relations  
Göschwitzer Straße 51 -52  
D-07745 Jena

Phone: +49 (0) 36 41 - 2 20 - 1 05

Fax: +49 (0) 36 41 - 2 20 -1 17

E-mail: [investors@meditec.zeiss.com](mailto:investors@meditec.zeiss.com)

Web: <http://www.meditec.zeiss.de>

**Press Release**